Opinion

Video

Episode 1: Advancing Patient Care in Non–Muscle-Invasive Bladder Cancer

Author(s):

Max Kates, MD

A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in patient care while highlighting recent treatment advances that offer promising solutions.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
      Strategies to bridge gender disparities in AAS and citations in the oncology literature
      Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead
      Reflecting on NMIBC Progress: Highlights From AUA 2025 and What’s Ahead
      Navigating Access Barriers: Resources to Support New Treatment Access
      Navigating Access Barriers: Resources to Support New Treatment Access
      Overcoming Challenges in Accessing New Therapies for NMIBC
      Overcoming Challenges in Accessing New Therapies for NMIBC
      1 expert in this video
      Selecting Between Receptor Pathway Inhibitors for mHSPC
      1 expert in this video
      The Use of Ultra-Low PSA in Specific Patient Profiles
      2 experts are featured in this series.
      The MOA of TLX250
      1 expert is featured in this series.
      The importance of studying efficacy and safety of treatment in Black patients with mHSPC
      2 experts are featured in this series.
      The ZIRCON Trial
      1 expert is featured in this series.
      Translating the Trial: How Findings from ARANOTE May Inform Treatment Decisions
      Related Content
      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
      June 12th 2025

      FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC

      Hannah Clarke
      The approval is supported by findings from the phase 3 ENVISION trial.
      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
      June 2nd 2025

      Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

      Amy M. Pearlman, MD
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 9th 2025

      En bloc resection of bladder tumor: Is it the way forward?

      Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery)
      "As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
      May 17th 2025

      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

      Amy M. Pearlman, MD Alex Tatem, MD
      Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
      FDA updates in urology: May 2025
      June 2nd 2025

      FDA updates in urology: May 2025

      Hannah Clarke
      A recap of the FDA submissions and regulatory decisions in urology from May 2025.
      Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
      June 1st 2025

      NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

      Benjamin P. Saylor
      The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
      © 2025 MJH Life Sciences

      All rights reserved.